
Ptc Therapeutics
(NASDAQ) PTCT
Ptc Therapeutics Financials at a Glance
Market Cap
$5.69B
Revenue (TTM)
$1.73B
Net Income (TTM)
$682.64M
EPS (TTM)
$7.74
P/E Ratio
8.88
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$68.77
Volume
587,617.459
Open
$71.57
Price
$68.77
Volume
587,617.459
Open
$71.57
Previous Close
$68.69
Daily Range
$68.22 - $71.57
52-Week Range
$35.95 - $87.50
Dividend
$0.00
Beta (Volatility)
0.99 (Low)
Price
$68.77
Volume
587,617.459
Open
$71.57
Previous Close
$68.69
Daily Range
$68.22 - $71.57
52-Week Range
$35.95 - $87.50
PTCT News




PTCT: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Ptc Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
991
CEO
Matthew B. Klein, MD
Website
www.ptcbio.comHeadquarters
Warren, NJ 07080, US
PTCT Financials
Key Financial Metrics (TTM)
Gross Margin
91%
Operating Margin
49%
Net Income Margin
39%
Return on Equity
0%
Return on Capital
44%
Return on Assets
23%
Earnings Yield
11.26%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$5.69B
Shares Outstanding
82.77M
Volume
587.62K
Short Interest
0.00%
Avg. Volume
1.16M
Financials (TTM)
Gross Profit
$1.66B
Operating Income
$856.51M
EBITDA
$887.66M
Operating Cash Flow
$711.20M
Capital Expenditure
$8.86M
Free Cash Flow
$702.34M
Cash & ST Invst.
$1.95B
Total Debt
$492.28M
Ptc Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$164.68M
-22.7%
Gross Profit
$148.38M
-24.6%
Gross Margin
90.10%
N/A
Market Cap
$5.69B
N/A
Market Cap/Employee
$6.06M
N/A
Employees
939
N/A
Net Income
$134.97M
-104.8%
EBITDA
$70.99M
-51.5%
Quarterly Fundamentals
Net Cash
$1.45B
+209.1%
Accounts Receivable
$181.62M
+14.5%
Inventory
$79.65M
+243.4%
Long Term Debt
$190.17M
-91.4%
Short Term Debt
$302.12M
+11.4%
Return on Assets
23.45%
N/A
Return on Invested Capital
44.09%
N/A
Free Cash Flow
$36.65M
-0.4%
Operating Cash Flow
$34.27M
-14.2%



